Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Predictive value of CD73 expression for the efficacy of immune checkpoint inhibitors in NSCLC.

Thoracic cancer - 1 Apr 2020

Ishii Hidenobu, Azuma Koichi, Kawahara Akihiko, Kinoshita Takashi, Matsuo Norikazu, Naito Yoshiko, Tokito Takaaki, Yamada Kazuhiko, Akiba Jun, Hoshino Tomoaki

Abstract excerpt

BACKGROUND: CD73 induces the dephosphorylation of adenosine monophosphate converting it to adenosine, enabling malignancies to escape from immune surveillance. Although CD73 overexpression has been reported to be a poor prognostic factor in several malignancies including non-small cell lung cancer (NSCLC), its predictive relevance in NSCLC patients receiving immune checkpoint inhibitors is unknown. The present...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to 5'-Nucleotidase
Share to Adenocarcinoma of Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma, Non-Small-Cell Lung

Share to Carcinoma, Squamous Cell

Share to ErbB Receptors

Share to GPI-Linked Proteins

Share to Immune Checkpoint Inhibitors

Share to Survival Rate

Source

Open in PubMed Open full text

Identifiers

PMID: 32061060
DOI: 10.1111/1759-7714.13346
PMCID: PMC7113063

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 11 closest

Predictive value of CD73 expression for the efficacy of immune checkpoint inhibitors in NSCLC.PMID 32061060Read ↗

The regulation of CD73 in non-small cell lung cancer.Semantic proximity Read ↗

Characterization of the Immune Landscape of EGFR-Mutant NSCLC Identifies CD73/Adenosine Pathway as a Potential Therapeutic Target.Semantic proximity Read ↗

Targeting CD73 to Overcomes Resistance to First-Generation EGFR Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer.Semantic proximity Read ↗

Anti-PD-L1 and anti-CD73 combination therapy promotes T cell response to EGFR-mutated NSCLC.Semantic proximity Read ↗

Targeting Immunometabolism Mediated by CD73 Pathway in EGFR-Mutated Non-small Cell Lung Cancer: A New Hope for Overcoming Immune Resistance.Semantic proximity Read ↗

Specific blockade CD73 alters the "exhausted" phenotype of T cells in head and neck squamous cell carcinoma.Semantic proximity Read ↗

MET-Induced CD73 Restrains STING-Mediated Immunogenicity of EGFR-Mutant Lung Cancer.Semantic proximity Read ↗

Predictive Markers for the Efficacy of Anti-PD-1/PD-L1 Antibodies in Lung Cancer.Semantic proximity Read ↗

Exploring the Expression of Adenosine Pathway-Related Markers CD73 and CD39 in Colorectal and Pancreatic Carcinomas Characterized by Multiplex Immunofluorescence: A Pilot StudySemantic proximity Read ↗

Effects of abnormal expression of CD73 on malignant phenotype of nasopharyngeal carcinoma.Semantic proximity Read ↗

The peripheral blood neutrophil-to-lymphocyte ratio is a prognostic predictor for survival of EGFR-mutant nonsmall cell lung cancer patients treated with EGFR-TKIs.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.